Please login to the form below

Not currently logged in
Email:
Password:

Tecentriq gains first IO approval in triple negative breast cancer

A coup for Roche in IO field dominated by Keytruda

Tecentriq

Roche has stolen a march on market leader Keytruda by gaining the first immuno-oncology approval in triple negative breast cancer.

Tecentriq (atezolizumab) can now be used in combination with chemotherapy (Celgene’s Abraxane, nab-paclitaxel) in adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and whose tumours express PD-L1, as determined by an FDA-approved test.

The green light comes via an accelerated approval based on progression-free survival (PFS), and Roche must follow up with a trial confirming the treatment’s overall survival benefits.

Nevertheless, the approval is a coup for Roche, which needs to break new ground in different tumour types in order to challenge the clinical and commercial juggernaut that is Keytruda, which earned over $7bn in sales last year, compared to Tecentriq’s $765m.

This is based on Keytruda’s tally of 14 FDA approvals, while the TNBC approval is Tecentriq’s fourth.

TNBC is certainly a large area of unmet medical need – it represents 15% of all the 2 million cases diagnosed each year breast cancers, and is more aggressive and has a worse prognosis than other breast cancer subtypes.

This accelerated approval is based on data from the phase 3 IMpassion130 study, which showed that Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death (PFS) by 40% compared with Abraxane alone in PD-L1-positive patients with unresectable locally advanced or metastatic TNBC who had not received prior chemotherapy for metastatic disease.

Overall survival (OS) results were immature with 43% of events in all randomised patients (intent-to-treat; ITT), and further data will be shared with the FDA and presented at an upcoming medical meeting. The company says safety in the Tecentriq plus nab-paclitaxel arm appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination.

The approval gives Roche a clear lead over Merck & Co, which has two studies in TNBC expected shortly: Keynote-522, which is testing the IO drug in combination with a range of chemotherapy regimens, plus Keynote-119, which is a trial of the drug as a monotherapy.

Roche is also hoping to achieve first-to-market in two other important settings: hepatocellular carcinoma (HCC), where analysts forecast a potential $1bn market opportunity for Tecentriq, and small cell lung cancer, where an FDA decision is expected by 18 March.

Article by
Andrew McConaghie

11th March 2019

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics